Skip to main content

Table 4 Cox proportional multivariate hazard model for relapse-free survival and breast cancer-specific survival

From: Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study

 

RFS

BCSS

Variable

No.

Hazard ratio (95 % CI)

P

Hazard ratio (95 % CI)

P

pTNMa

215

    

 0–1

 

1.0

 

1.0

 

 2

 

1.77 (0.89–3.53)

NS

1.36 (0.49–3.80)

NS

 3–4

 

4.09 (1.69–9.90)

<0.05

3.37 (1.30–9.31)

<0.05

HG

215

    

 1

 

1.0

 

1.0

 

 2

 

2.35 (0.47–11.72)

NS

1.84 (0.32–10.52)

NS

 3

 

26.98(5.82–125.12)

<0.001

19.21 (4.15–88.90)

<0.001

Hormone receptor

215

    

 ER+ PR+

 

1.0

 

1.0

 

 ER+ or PR+

 

1.53 (0.70–3.33)

NS

1.63 (0.74–3.57)

NS

 ER− PR−

 

3.31 (1.28–8.58)

<0.05

2.94 (1.17–7.41)

<0.05

pCR

215

    

 Yes

 

1.0

 

1.0

 

 No

 

1.53 (1.09–5.65)

<0.05

3.37(1.93–28.26)

<0.05

Surgery

215

    

 Breast-conserving surgery

 

1.0

 

1.0

 

 Modified mastectomy

 

0.80 (0.33–1.92)

NS

0.77 (0.29–2.05)

NS

NLR (before NAC)

215

    

 NLR < 2.1

 

1.0

 

1.0

 

 NLR ≥ 2.1

 

1.57 (1.05–3.57)

<0.05

2.21 (1.01–4.39)

<0.05

CRP (before NAC)

215

1.02 (0.99–1.05)

NS

1.00 (0.97–1.04)

NS

  1. apT, pN, pTNM are pathological stages after surgery